Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
119 hedge funds and large institutions have $990M invested in Constellation Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 57 increasing their positions, 23 reducing their positions, and 28 closing their positions.
6,614% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $211K
148% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 23
10% less funds holding
Funds holding: 132 → 119 (-13)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
31% less capital invested
Capital invested by funds: $1.44B → $990M (-$455M)
43% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$19.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.36M |
| 3 |
Millennium Management
New York
|
+$6.78M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$6.71M |
| 5 |
First Manhattan
New York
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$42.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.65M |
CNST Hedge Fund Activity: Q3 2020 in Review
119 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q3 2020, worth a combined $990M — down 31% from $1.44B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CNST and 16 opened new positions — a net loss of 12 holders — while 23 trimmed existing stakes and 57 added.
The largest buyer was State Street, adding an estimated $19.2M. The largest seller was TRV GP, exiting entirely with an estimated $42.1M sold.
- 119 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q3 2020, down from 132 in Q2 2020.
- Funds reported $990M of Constellation Pharmaceuticals, Inc. stock for Q3 2020, down 31% quarter-over-quarter.
- 16 funds opened new Constellation Pharmaceuticals, Inc. positions in Q3 2020 and 28 closed out, a net change of -12 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q3 2020 was State Street, an estimated $19.2M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q3 2020 was TRV GP, an estimated $42.1M sold.
Based on aggregated 13F filings for Q3 2020.